Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: A short-term, low dose, randomized, placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 28, Issue 4, 2008, Pages 406-410

  Altamura, Alfredo Carlo ^a   Dell'Osso, Bernardo ^a   Buoli, Massimiliano ^a   Zanoni, Silvia ^a   Mundo, Emanuela ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT;

ADD ON THERAPY; ANXIETY; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; TREATMENT RESPONSE; XEROSTOMIA; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIDEPRESSIVE AGENTS; CITALOPRAM; CLOMIPRAMINE; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; SEROTONIN UPTAKE INHIBITORS;

EID: 54449101151     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31817d5931     Document Type: Article

References (35)

1. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62:5-9.
2. Gayetot D, Ansseau M, Triffaux JM. When depression does not end. Resistant depression: recent clinical and therapeutic aspects. Rev Med Liege. 2007;62:103-111.
3. Fava M, Davidson KG. Definition and epidemiology of treatment- resistant depression. Psychiatr Clin North Am. 1996;19:179-200.
4. Sackeim HA. The definition and meaning of treatment-resistant depression. JClin Psychiatry. 2001;62:10-17.
5. Amsterdam JD, Horning M, Nierenberg AA. Treatment-Resistant Mood Disorders. Cambridge, UK: Cambridge University Press; 2001.
6. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
7. Zimmerman M, Posternak M, Chelminski I. Heterogeneity among depressed outpatients considered to be in remission. Compr Psychiatry. 2007;48:113-117.
8. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006; 354:1243-1252.
9. Preskorn SH, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry. 1992;53:10.
10. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry. 2000;157:1-45.
11. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br JPsychiatry. 1993;162:634-640.
12. Bauer M, Adli M, Baethge C, et al. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can JPsychiatry. 2003;48:440-448.
13. Bauer M. Thyroid hormone augmentation with levothyroxine in bipolar depression. Bipolar Disord. 2002;4:109-110.
14. Worthington JJ 3rd, Kinry AG, Wygant LE, et al. Aripripazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005;20:9-11.
15. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepres-santdrugs in the treatmentofmajordepression. JClin Psychopharmacol. 1995;15:217-222.
16. Thase ME, Fava M, De Battista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12 week, open label, extension study. CNS Spectr. 2006;11:93-102.
17. Moukaddam NJ, Hirschfeld RM. Intravenous antidepressants: a review. Depress Anxiety. 2004;19:1-9.
18. Charbonnier JF, Rebuol P, Rougier M, et al. Citalopram: an open trial of a highly selective 5-HT uptake inhibitor, administrated intravenously to depressed patients. Encephale. 1987;13:249-254.
19. Baumann P, Nil R, Bertschy G. A double-blind, double-dummy study of citalopram comparing infusion versus oral administration. J Affect Disord. 1998;49:203-210.
20. Kasper S, Müller-Spahn F. Intravenous antidepressant treatment: focus on citalopram. Eur Arch Psychiatry Clin Neurosci. 2002;252:105-109.
21. Kelly MW, Myers CW. Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder. DICP. 1990;24:739-744.
22. McTavish D, Benfield P. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs. 1990;39:136-153.
23. De Cuyper HJ, Van Praag HM, Mulder-Hajonides WR, et al. Pharmacokinetics of clomipramine in depressive patients. Psychiatry Res. 1981;4:147-156.
24. Pollock BG, Perel JM, Nathan RS, et al. Acute antidepressant effect following pulse loading with intravenous and oral clomipramine. Arch Gen Psychiatry. 1989;46:29-35.
25. Nunez R, Perel JM. Comparative neurotransmitter reuptake and anticholinergic potencies of the 8-hydroxy metabolites of clomipramine. Psychopharmacol Bull. 1995;31:217-221.
26. Altamura AC, Zanoni S, Bosi M, et al. Augmentative intravenous clomipramine in partial responder major depressive: a single blind, placebo controlled study. Shown at 159th meeting of the American Psychiatry Association; May 20-25, 2006; Toronto, ON.
27. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders. Arlington, VA: American Psychiatric Publishing Inc; 1997.
28. Schatzberg AF, Nemeroff CB. Essentials of Clinical Psychopharmacology. Arlington, VA: American Psychiatric Publishing Inc; 2006.
29. Sallee FR, Vrindavanam NS, Deas-Nesmith D, et al. Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial. Am J Psychiatry. 1997;154(5):668-673.
30. Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res. 1995;31:347-353.
31. Charlier C, Pinto E, Ansseau M, et al. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol. 2000;15:453-459.
32. Suhara A, Takano A, Sudo I, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003;60:386-391.
33. Svetska J, Ceskova E, Kamenicka V, et al. Citalopram (Seropram) in tablet and infusion forms in the treatment of major depression. Cesk Psychiatr. 1993;89:331-339.
34. Stahl SM. Essential Psychopharmacology-The Prescriber's Guide. Cambridge University Press; 2005;63-67.
35. Lundberg J, Christophersen JS, Petersen KB, et al. PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. Int JNeuropsychopharmacol. 2007;10(6):777-785.